Every Form 4 that Hemab Therapeutics Holdings, Inc. (COAG) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow COAG and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full COAG filings page.
Hemab Therapeutics Holdings, Inc. director Walbert Keli received a stock option award covering 36,000 shares of common stock on September 24, 2026. The exercise price is $35.72 per share, and the resulting option position covers 36,000 underlying shares. The option vests in equal monthly installments over three years, from September 24, 2026 through September 24, 2029, subject to continuous service, and expires September 23, 2036. No Rule 10b5-1 plan is reported.
Hemab Therapeutics Holdings, Inc. reported that investment entities affiliated with RA Capital Management, a ten percent owner, made open-market purchases of Common Stock. On June 16, 2026, an affiliated fund bought 61,523 shares at a weighted average price of $24.98 per share, with trades ranging from $24.55 to $25.00. On June 15, 2026, another affiliated fund bought 6,146 shares at a weighted average price of $24.89 per share, within a $24.65 to $25.00 range. Following these transactions, one indirect position reported 6,444,637 shares, while related fund holdings were reported at 354,938 and 1,009,052 shares, all held indirectly and subject to pecuniary-interest-only ownership disclaimers.
Hemab Therapeutics Holdings, Inc. disclosed that investment vehicles associated with RA Capital made open-market purchases of its Common Stock. On May 19, an RA Capital-related entity bought 3,802 shares at a weighted average price of $24.97 per share, and on May 20 another purchase of 996 shares was made at a weighted average price of $24.94 per share. Following these transactions, RA Capital-affiliated entities indirectly held 6,376,968 shares of Hemab Therapeutics Common Stock. The filing notes that shares are held directly by RA Capital Healthcare Fund, L.P. and RA Capital Nexus funds, and that the Adviser, its general partner, and principals disclaim beneficial ownership of the reported securities except to the extent of any pecuniary interest.
Hemab Therapeutics Holdings, Inc. reported an insider open-market purchase by entities managed by RA Capital Management. An RA Capital-affiliated fund bought 6,387 shares of common stock at a weighted average price of $24.90 per share, with trade prices ranging from $24.70 to $25.00. Following this transaction, the fund indirectly holds 6,372,170 shares of Hemab Therapeutics common stock, while related Nexus funds report indirect holdings of 354,938 and 1,009,052 shares. RA Capital Management, its general partner, and individuals Peter Kolchinsky and Rajeev Shah disclaim beneficial ownership of these securities except to the extent of their pecuniary interest.
Hemab Therapeutics Holdings, Inc. reported multiple open-market purchases of its Common Stock by entities associated with RA Capital. Over May 7–11, RA Capital–managed funds bought a total of 51,258 shares at weighted average prices generally between about $23.78 and $25.00 per share, across several transaction ranges noted in the footnotes. Following these purchases, RA Capital–related entities reported indirect ownership of 6,365,783 shares of Hemab common stock. Shares are held directly by RA Capital Healthcare Fund LP, RA Capital Nexus II Fund LP, and RA Capital Nexus IV Fund LP, while RA Capital Management, L.P., its general partner, and principals Peter Kolchinsky and Rajeev Shah act as investment managers and disclaim beneficial ownership except to the extent of their pecuniary interests.
Hemab Therapeutics Holdings, Inc. reported that funds managed by RA Capital increased their indirect stake through a mix of open‑market purchases and preferred stock conversions. Over May 4–6, 2026, the funds bought 2,840,429 shares of common stock at prices including $18.00, $24.59, $25.00, $23.77 and $24.83 per share. In connection with the issuer’s initial public offering, all Series A, B and C preferred shares automatically converted to common stock on a 22‑for‑1 basis for no additional consideration. Following these transactions, indirect holdings reported in one line reached 6,314,525 shares of common stock.
Hemab Therapeutics Holdings, Inc. reported that Chief Medical Officer Catherine Madigan received new equity awards. She was granted 145,134 warrants to buy common stock at $6.00 per share, expiring on January 28, 2036. The shares underlying this warrant vest over four years, with 25% vesting on January 1, 2027 and the remainder in equal monthly installments.
Madigan was also granted a stock option for 49,016 shares of common stock at an exercise price of $18.00 per share, expiring on April 29, 2036. These option shares vest in equal monthly installments over four years from May 1, 2026 through May 1, 2030. Both awards are structured as long-term compensation rather than open-market purchases or sales.